한글목차

세계의 정신 질환 치료 시장의 미래는 병원 약국, 소매 약국, 드러그스토어, E-Commerce 시장에서의 기회로 유망시되고 있습니다. 세계의 정신 질환 치료 시장은 2025-2031년에 CAGR 6.1%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 정신질환의 유병률 증가, 정신과 치료에 대한 인식 증가, 효과적인 의약품에 대한 수요 증가 등입니다.

• Lucintel의 예측에 따르면 약물 유형별로는 비정형 항정신병제물이 예측 기간 중 가장 높은 성장세를 보일 것으로 예측됩니다.
• 유통채널별로는 병원약국이 가장 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 중 가장 높은 성장을 보일 것으로 예측됩니다.

정신질환 치료 시장의 새로운 동향

정신질환 치료 시장은 약품 개발의 획기적인 발전, 개인 맞춤형 치료의 중요성 증가, 디지털 기술의 통합을 특징으로 하는 역동적인 변화를 경험하고 있습니다. 이러한 새로운 동향은 치료 패러다임을 재정의하고, 정신질환을 관리하기 위한 보다 종합적이고 접근하기 쉬운 접근법을 촉진하고 있습니다.

• 신규 약물요법 및 작용기전: 이러한 추세는 기존의 도파민 길항작용을 넘어 새로운 생물학적 경로를 표적으로 하는 항정신병제물의 개발에 관여하고 있습니다. 예를 들어 무스카린성 아세틸콜린 수용체에 작용하는 약물(M1/M4 작용제)이 유망하게 여겨지고 있으며, 양성 증상, 음성 증상, 인지 증상에 대해 더 적은 부작용으로 더 우수한 효과를 나타낼 가능성이 있습니다.
• 지속성 주사 항정신병제물: 항정신병제물의 LAI 제제 개발 및 채택이 증가하고 있는 것은 중요한 추세입니다. LAI는 만성 정신질환 관리의 큰 과제인 투약 횟수를 줄임으로써 복약 순응도를 개선하고, 치료 성적 향상과 재발률 감소로 이어집니다.
• 디지털 치료와 원격 정신의학: 증상 추적을 위한 모바일 앱, 가상현실(VR) 치료, 원격 정신의학 등 디지털 헬스 솔루션의 통합은 새로운 동향입니다. 이러한 기술은 환자와의 관계를 강화하고, 원격 지원을 제공하며, 치료 접근성을 개선하고, 특히 의료 서비스가 부족한 지역의 환자들에게 개별화된 개입을 제공합니다.
• 맞춤형 의료 접근법: 이 동향은 유전자 프로파일, 바이오마커 등 환자 개개인의 특성에 따라 치료 계획을 조정하는 데 초점을 맞추었습니다. 환자의 질병에 관여하는 특정 경로를 파악하여 약물의 선택, 복용량을 최적화하고 부작용을 줄이는 것을 목표로 하는 맞춤형 의료는 보다 효과적이고 맞춤 치료로 이어질 수 있습니다.
• 심리사회적 개입의 통합: 약물 치료와 인지행동치료(CBT), 가족심리교육, 취업지원 등 종합적인 심리사회적 개입과의 통합이 강조되고 있습니다. 이러한 추세는 증상뿐만 아니라 기능 회복과 환자의 삶의 질 향상에 초점을 맞춘 전인적 접근을 촉진하는 것입니다.

이러한 새로운 동향은 보다 효과적이고 효과적인 약리학적 개입, 혁신적인 약물전달을 통한 환자 순응도 향상, 디지털 헬스(Digital Health)를 통한 접근성 및 참여도 향상, 치료에 대한 총체적이고 개별화된 접근 방식 촉진 등을 통해 정신질환 치료 시장을 크게 재편할 것으로 예측됩니다. 정신질환 치료제 시장을 재편하고 있습니다.

정신질환 치료 시장의 최근 동향

최근 정신질환 치료제 시장은 효능 개선, 환자 순응도 향상, 정신 헬스케어에 대한 보다 종합적인 접근 방식을 향한 업계의 강력한 추진력을 반영하여 몇 가지 매우 중요한 진전을 이루었습니다. 이러한 발전은 정신질환 환자의 복잡한 요구에 대응하기 위해 매우 중요합니다.

• 새로운 기전의 항정신병제물의 FDA 승인: FDA가 새로운 기전의 항정신병제물을 승인한 것은 중요한 진전입니다. 예를 들어 크사노멜린 트로스피움은 도파민 수용체만 표적으로 삼는 것이 아니라 콜린성 수용체를 표적으로 삼습니다. 이는 패러다임의 전환을 의미하며, 더 나은 효과와 다른 부작용 프로파일을 가져올 수 있습니다.
• 지속형 주사제의 발전: 최근 지속형 주사제 항정신병제물의 기술 혁신과 신규 승인이 계속되고 있습니다. 팔미틴산 팔리페리돈의 새로운 버전(Invega Hafyera 등)으로 대표되는 이들 제제는 투여 간격을 연장하여 복약 순응도를 개선하고, 재발률을 낮추며, 치료를 보다 편리하게 하는 것을 목표로 합니다.
• 정신질환에 대한 디지털 치료와 VR의 성장: 기존 치료를 보완하기 위해 디지털 치료제 및 가상현실(VR) 솔루션의 개발 및 적용이 진행되고 있습니다. 예를 들어 OxfordVR의 gamechanger VR은 몰입형 가상 시나리오에서 자동화된 CBT를 제공하여 편집증 완화 및 QOL 개선에 큰 효과가 있는 것으로 나타났습니다.
• 음성 증상과 인지 증상에 대한 초점: 최근 연구개발에서 정신질환의 음성 증상과 인지 증상을 대상으로 하는 노력이 증가하고 있습니다. 기업은 일상 생활에 큰 영향을 미치는 이러한 쇠약 증상을 개선하기 위해 새로운 화합물과 접근법을 모색하고 있습니다.
• 전략적 제휴 및 파이프라인 성장: 제약사들은 의약품 개발을 가속화하기 위해 전략적 제휴 및 공동연구를 진행하고 있습니다. 베링거인겔하임과 소성그룹과의 조현병 치료제 GPR52 작용제 공동연구는 그 한 예로서, 다양한 증상에 대응하는 강력한 신약 파이프라인을 보여주고 있습니다.

이러한 최근 동향은 다양한 기전을 통한 새로운 치료 옵션의 도입, 첨단 제형을 통한 복약 순응도 강화, 디지털 헬스 활용을 통한 접근성 및 결과 개선, 미충족 증상 영역에 대한 집중적인 노력 등 정신질환 치료 시장에 전반적으로 영향을 미치고 있으며 궁극적으로 전인적 환자 치료를 촉진할 수 있을 것으로 기대됩니다.

목차

제1장 개요

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 정신 질환 치료 시장 : 약제 유형별

• 개요
• 매력 분석 : 약제 유형별
• 비정형 항정신병약 : 동향과 예측(2019-2031년)
• 페노티아진계 항정신병약 : 동향과 예측(2019-2031년)
• Thioxanthenes : 동향과 예측(2019-2031년)
• 기타 항정신병약 : 동향과 예측(2019-2031년)

제5장 세계의 정신 질환 치료 시장 : 적응증별

• 개요
• 매력 분석 : 적응증별
• 조현병 : 동향과 예측(2019-2031년)
• 양극성 장애 : 동향과 예측(2019-2031년)
• 망상성 장애 : 동향과 예측(2019-2031년)
• 약물 유발성 정신병 : 동향과 예측(2019-2031년)
• 유기성 정신병 : 동향과 예측(2019-2031년)

제6장 세계의 정신 질환 치료 시장 : 유통 채널별

• 개요
• 매력 분석 : 유통 채널별
• 병원 약국 : 동향과 예측(2019-2031년)
• 소매 약국 : 동향과 예측(2019-2031년)
• 드러그스토어 : 동향과 예측(2019-2031년)
• E-Commerce : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031)

제7장 지역 분석

• 개요
• 세계의 정신 질환 치료 시장 : 지역별

제8장 북미의 정신 질환 치료 시장

• 개요
• 북미의 정신 질환 치료 시장 : 약제 유형별
• 북미의 정신 질환 치료 시장 : 유통 채널별
• 미국의 정신 질환 치료 시장
• 멕시코의 정신 질환 치료 시장
• 캐나다의 정신 질환 치료 시장

제9장 유럽의 정신 질환 치료 시장

• 개요
• 유럽의 정신 질환 치료 시장 : 약제 유형별
• 유럽의 정신 질환 치료 시장 : 유통 채널별
• 독일의 정신 질환 치료 시장
• 프랑스의 정신 질환 치료 시장
• 스페인의 정신 질환 치료 시장
• 이탈리아의 정신 질환 치료 시장
• 영국의 정신 질환 치료 시장

제10장 아시아태평양의 정신 질환 치료 시장

• 개요
• 아시아태평양의 정신 질환 치료 시장 : 약제 유형별
• 아시아태평양의 정신 질환 치료 시장 : 유통 채널별
• 일본의 정신 질환 치료 시장
• 인도의 정신 질환 치료 시장
• 중국의 정신 질환 치료 시장
• 한국의 정신 질환 치료 시장
• 인도네시아의 정신 질환 치료 시장

제11장 세계 기타 지역(ROW)의 정신 질환 치료 시장

• 개요
• ROW의 정신 질환 치료 시장 : 약제 유형별
• ROW의 정신 질환 치료 시장 : 유통 채널별
• 중동의 정신 질환 치료 시장
• 남미의 정신 질환 치료 시장
• 아프리카의 정신 질환 치료 시장

제12장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간 경쟁 관계
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제13장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 약제 유형별 성장 기회
  • 적응증별 성장 기회
  • 유통 채널별 성장 기회
• 세계의 정신 질환 치료 시장에서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증과 라이선싱
  • 합병, 인수, 계약, 제휴, 합병사업

제14장 밸류체인에서 주요 기업의 기업 개요

• Competitive Analysis
• H. Lundbeck
• Otsuka Pharmaceutical
• Janssen Pharmaceuticals
• Eli Lilly and Company
• Allergan
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Sumitomo Dainippon Pharma
• Alkermes
• Bristol-Myers Squibb Company

제15장 부록

• 도표
• 표 리스트
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위

영문목차

The future of the global psychotic disorder treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, drug store and e-commerce markets. The global psychotic disorder treatment market is expected to grow with a CAGR of 6.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of mental health disorders, the rising awareness about psychiatric treatments, and the growing demand for effective medications.

• Lucintel forecasts that, within the drug type category, atypical antipsychotic is expected to witness the highest growth over the forecast period.
• Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Psychotic Disorder Treatment Market

The psychotic disorder treatment market is experiencing dynamic shifts, characterized by significant advancements in drug development, a growing emphasis on personalized care, and the integration of digital technologies. These emerging trends are redefining treatment paradigms and fostering a more holistic and accessible approach to managing mental health conditions.

• Novel Drug Therapies and Mechanisms of Action: This trend involves the development of antipsychotic medications targeting new biological pathways beyond traditional dopamine antagonism. For instance, drugs acting on muscarinic acetylcholine receptors (M1/M4 agonists) are showing promise, offering potentially better efficacy for positive, negative, and cognitive symptoms with fewer side effects.
• Long-Acting Injectable Antipsychotics: The increasing development and adoption of LAI formulations for antipsychotic drugs is a significant trend. LAIs improve medication adherence by reducing the frequency of dosing, which is a major challenge in managing chronic psychotic disorders, leading to better treatment outcomes and reduced relapse rates.
• Digital Therapeutics and Telepsychiatry: The integration of digital health solutions, including mobile apps for symptom tracking, virtual reality (VR) therapy, and telepsychiatry, is an emerging trend. These technologies enhance patient engagement, provide remote support, improve access to care, and offer personalized interventions, particularly for individuals in underserved areas.
• Personalized Medicine Approaches: This trend focuses on tailoring treatment plans based on individual patient characteristics, including genetic profiles and biomarkers. By identifying specific pathways involved in a patient's illness, personalized medicine aims to optimize drug selection, dosage, and reduce adverse effects, leading to more effective and individualized care.
• Integration of Psychosocial Interventions: There's a growing emphasis on integrating pharmacotherapy with comprehensive psychosocial interventions, such as cognitive-behavioral therapy (CBT), family psychoeducation, and supported employment. This trend promotes a holistic approach, addressing not only symptoms but also functional recovery and improving quality of life for patients.

These emerging trends are profoundly reshaping the psychotic disorder treatment market by offering more targeted and effective pharmacological interventions, improving patient adherence through innovative drug delivery, enhancing accessibility and engagement via digital health, and promoting a holistic, personalized approach to care.

Recent Developments in the Psychotic Disorder Treatment Market

The psychotic disorder treatment market has witnessed several pivotal recent developments, reflecting a strong industry drive towards improved efficacy, enhanced patient compliance, and a more comprehensive approach to mental health care. These advancements are crucial for addressing the complex needs of individuals with psychotic disorders.

• FDA Approval of Novel Mechanism Antipsychotics: A significant development is the FDA approval of antipsychotic drugs with new mechanisms of action, such as xanomeline-trospium, which targets cholinergic receptors instead of solely dopamine receptors. This represents a paradigm shift, offering potentially better efficacy and a different side effect profile.
• Advancements in Long-Acting Injectable Formulations: Recent years have seen continued innovation and new approvals for long-acting injectable antipsychotics. These formulations, such as new versions of paliperidone palmitate (e.g., Invega Hafyera), aim to improve adherence and reduce relapse rates by offering extended dosing intervals, making treatment more convenient.
• Growth in Digital Therapeutics and VR for Psychosis: There's an increasing development and application of digital therapeutics and virtual reality (VR) solutions to complement traditional treatments. For instance, OxfordVR's gamechanger VR offers automated CBT in immersive virtual scenarios, demonstrating significant benefits in reducing paranoia and improving quality of life.
• Focus on Negative and Cognitive Symptoms: Recent R&D efforts are increasingly targeting the negative and cognitive symptoms of psychotic disorders, which are often poorly addressed by existing medications. Companies are exploring novel compounds and approaches to improve these debilitating symptoms, which significantly impact daily functioning.
• Strategic Collaborations and Pipeline Growth: Pharmaceutical companies are engaging in more strategic partnerships and collaborations to accelerate drug development. Boehringer Ingelheim and Sosei Group Corporation's collaboration on GPR52 agonists for schizophrenia is an example, indicating a robust pipeline of new therapies addressing various symptoms.

These recent developments are collectively impacting the psychotic disorder treatment market by introducing novel treatment options with different mechanisms, enhancing medication adherence through advanced formulations, leveraging digital health for improved access and outcomes, and focusing on underserved symptom domains, ultimately advancing holistic patient care.

Strategic Growth Opportunities in the Psychotic Disorder Treatment Market

The psychotic disorder treatment market presents numerous strategic growth opportunities across key applications, driven by increasing disease prevalence, a focus on improving patient outcomes, and advancements in therapeutic approaches. Capitalizing on these opportunities requires targeted innovation and a patient-centric approach.

• Schizophrenia Treatment Innovations: Schizophrenia remains a primary application with significant growth potential. Opportunities exist in developing new antipsychotics with improved efficacy for negative and cognitive symptoms, long-acting injectables for better adherence, and personalized medicine approaches based on genetic markers to optimize treatment.
• Bipolar Disorder Management: The segment for bipolar disorder treatment offers substantial growth, particularly in developing novel mood stabilizers and atypical antipsychotics that provide comprehensive symptom control with fewer side effects. There's a need for therapies that effectively manage both manic and depressive episodes.
• Early Intervention and First-Episode Psychosis: Focusing on early intervention programs and treatments for first-episode psychosis is a crucial growth area. Early and effective treatment can significantly alter disease trajectory, improve long-term outcomes, and reduce the burden of illness, creating a demand for rapid diagnostic and therapeutic interventions.
• Treatment-Resistant Psychosis: A significant unmet need exists for effective treatments for patients with treatment-resistant psychosis. Strategic opportunities involve developing novel compounds or combination therapies that can address this challenging patient population, potentially through different pharmacological pathways or augmentation strategies.
• Digital Health Integration: Leveraging digital therapeutics, telemedicine, and remote monitoring platforms offers immense growth potential. These applications can improve medication adherence, provide continuous symptom tracking, facilitate psychotherapy delivery, and enhance access to care, especially for patients in underserved areas or those preferring discreet support.

These strategic growth opportunities are profoundly impacting the psychotic disorder treatment market by directing R&D towards unmet needs, fostering innovation in drug delivery, and integrating digital solutions to enhance patient engagement and access. This diversification and patient-centric approach are crucial for advancing mental health care globally.

Psychotic Disorder Treatment Market Driver and Challenges

The psychotic disorder treatment market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. Its growth trajectory is significantly propelled by drivers that boost demand and innovation, while simultaneously facing notable challenges that necessitate strategic adaptations for sustained expansion and broader market penetration.

The factors responsible for driving the psychotic disorder treatment market include:

1. Increasing Prevalence of Psychotic Disorders: The rising global incidence and diagnosis of psychotic disorders like schizophrenia and bipolar disorder are primary market drivers. Factors such as changing lifestyles, increased stress, and improved diagnostic capabilities contribute to an expanding patient pool requiring treatment.

2. Advancements in Antipsychotic Drug Development: Continuous R&D leading to newer generations of antipsychotics (atypical, third-generation) with improved efficacy, better side effect profiles, and novel mechanisms of action is a significant driver. This includes the development of long-acting injectables (LAIs) enhancing adherence.

3. Growing Awareness and Destigmatization of Mental Health: Increased public awareness campaigns, government initiatives, and reduced stigma surrounding mental illness encourage more individuals to seek diagnosis and treatment. This improved access to care directly translates into higher demand for therapeutic interventions.

4. Favorable Reimbursement Policies and Healthcare Spending: Enhanced healthcare coverage and increased government and private sector spending on mental health services in many countries are driving market growth. This improves patient access to medications and therapeutic support, especially in developed economies.

5. Integration of Digital Health and Telepsychiatry: The rapid adoption of digital therapeutics and telepsychiatry platforms, especially accelerated by recent global health events, significantly drives market access. These technologies facilitate remote consultations, medication management, and psychological support, overcoming geographical barriers.

Challenges in the psychotic disorder treatment market are:

1. High Cost of Novel Therapies: The development and commercialization of new, innovative antipsychotic drugs, particularly those with complex mechanisms or advanced formulations like LAIs, entail high R&D costs, leading to high prices that can limit patient access and reimbursement in some healthcare systems.

2. Medication Non-Adherence and Relapse Rates: Despite advancements, non-adherence to medication remains a significant challenge in managing chronic psychotic disorders, leading to frequent relapses and poorer patient outcomes. This necessitates continuous efforts in developing more convenient formulations and supportive interventions.

3. Persistent Stigma and Misconceptions: Despite growing awareness, societal stigma and misconceptions surrounding psychotic disorders can still deter individuals from seeking early diagnosis and consistent treatment. This impacts treatment initiation, adherence, and overall patient integration into society.

The psychotic disorder treatment market is dynamically driven by the increasing prevalence of mental illnesses, continuous innovation in drug development, and growing mental health awareness. However, significant challenges such as the high cost of advanced therapies, persistent issues with medication non-adherence, and enduring societal stigma demand concerted efforts from pharmaceutical companies, healthcare providers, and policymakers to ensure equitable access and optimal patient outcomes.

List of Psychotic Disorder Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies psychotic disorder treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the psychotic disorder treatment companies profiled in this report include-

• H. Lundbeck
• Otsuka Pharmaceutical
• Janssen Pharmaceuticals
• Eli Lilly and Company
• Allergan
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Sumitomo Dainippon Pharma
• Alkermes
• Bristol-Myers Squibb Company

Psychotic Disorder Treatment Market by Segment

The study includes a forecast for the global psychotic disorder treatment market by drug type, indication, distribution channel, and region.

Psychotic Disorder Treatment Market by Drug Type [Value from 2019 to 2031]:

• Atypical Antipsychotics
• Phenothiazine Antipsychotics
• Thioxanthenes
• Miscellaneous Antipsychotics Agents

Psychotic Disorder Treatment Market by Indication [Value from 2019 to 2031]:

• Schizophrenia
• Bipolar Disorder
• Delusional Disorder
• Drug Induced Psychosis
• Organic Psychosis

Psychotic Disorder Treatment Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Psychotic Disorder Treatment Market

The psychotic disorder treatment market is witnessing a profound transformation, driven by an escalating global prevalence of mental health conditions, increasing awareness, and significant advancements in pharmacotherapy and digital health solutions. This evolution is marked by a shift towards more targeted, patient-centric, and accessible treatment options, aiming to improve adherence and long-term outcomes for individuals living with conditions like schizophrenia and bipolar disorder.

• United States: The U.S. market is a leader in adopting novel treatments, including long-acting injectables (LAIs) and new mechanisms of action. High healthcare spending and robust R&D by pharmaceutical companies are driving innovations, with a focus on addressing treatment-resistant cases and improving patient adherence through advanced formulations.
• China: China market is rapidly expanding, fueled by a growing patient pool and increasing government investment in mental healthcare infrastructure. Local pharmaceutical companies are developing generic versions of antipsychotics, while also exploring digital health solutions to improve access and reduce the stigma associated with mental health treatment.
• Germany: Germany market benefits from a well-established healthcare system and a strong emphasis on comprehensive mental health care. There's a growing adoption of advanced antipsychotics, coupled with integrated care models that combine pharmacotherapy with psychosocial interventions to improve patient outcomes and quality of life.
• India: India market for psychotic disorder treatment is nascent but growing, driven by increasing awareness and government initiatives to destigmatize mental illness. Demand for affordable generic antipsychotics is high, while increasing investments in R&D are slowly bringing newer, more effective treatments to a larger patient population.
• Japan: Japan market is characterized by a high focus on precision medicine and patient compliance. Japanese pharmaceutical companies are at the forefront of developing novel compounds and advanced formulations, particularly long-acting injectables, aimed at improving treatment adherence and reducing side effects for long-term management.

Features of the Global Psychotic Disorder Treatment Market

• Market Size Estimates: Psychotic disorder treatment market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Psychotic disorder treatment market size by drug type, indication, distribution channel, and region in terms of value ($B).
• Regional Analysis: Psychotic disorder treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different drug type, indication, distribution channel, and regions for the psychotic disorder treatment market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the psychotic disorder treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the psychotic disorder treatment market by drug type (atypical antipsychotics, phenothiazine antipsychotics, thioxanthenes, and miscellaneous antipsychotics agents), indication (schizophrenia, bipolar disorder, delusional disorder, drug induced psychosis, and organic psychosis), distribution channel (hospital pharmacies, retail pharmacies, drug store, e-commerce, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Psychotic Disorder Treatment Market by Drug Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Drug Type
• 4.3 Atypical Antipsychotics: Trends and Forecast (2019-2031)
• 4.4 Phenothiazine Antipsychotics: Trends and Forecast (2019-2031)
• 4.5 Thioxanthenes: Trends and Forecast (2019-2031)
• 4.6 Miscellaneous Antipsychotics Agents: Trends and Forecast (2019-2031)

5. Global Psychotic Disorder Treatment Market by Indication

• 5.1 Overview
• 5.2 Attractiveness Analysis by Indication
• 5.3 Schizophrenia: Trends and Forecast (2019-2031)
• 5.4 Bipolar Disorder: Trends and Forecast (2019-2031)
• 5.5 Delusional Disorder: Trends and Forecast (2019-2031)
• 5.6 Drug Induced Psychosis: Trends and Forecast (2019-2031)
• 5.7 Organic Psychosis: Trends and Forecast (2019-2031)

6. Global Psychotic Disorder Treatment Market by Distribution Channel

• 6.1 Overview
• 6.2 Attractiveness Analysis by Distribution Channel
• 6.3 Hospital Pharmacies: Trends and Forecast (2019-2031)
• 6.4 Retail Pharmacies: Trends and Forecast (2019-2031)
• 6.5 Drug Store: Trends and Forecast (2019-2031)
• 6.6 e-Commerce: Trends and Forecast (2019-2031)
• 6.7 Others: Trends and Forecast (2019-2031)

7. Regional Analysis

• 7.1 Overview
• 7.2 Global Psychotic Disorder Treatment Market by Region

8. North American Psychotic Disorder Treatment Market

• 8.1 Overview
• 8.2 North American Psychotic Disorder Treatment Market by Drug Type
• 8.3 North American Psychotic Disorder Treatment Market by Distribution Channel
• 8.4 United States Psychotic Disorder Treatment Market
• 8.5 Mexican Psychotic Disorder Treatment Market
• 8.6 Canadian Psychotic Disorder Treatment Market

9. European Psychotic Disorder Treatment Market

• 9.1 Overview
• 9.2 European Psychotic Disorder Treatment Market by Drug Type
• 9.3 European Psychotic Disorder Treatment Market by Distribution Channel
• 9.4 German Psychotic Disorder Treatment Market
• 9.5 French Psychotic Disorder Treatment Market
• 9.6 Spanish Psychotic Disorder Treatment Market
• 9.7 Italian Psychotic Disorder Treatment Market
• 9.8 United Kingdom Psychotic Disorder Treatment Market

10. APAC Psychotic Disorder Treatment Market

• 10.1 Overview
• 10.2 APAC Psychotic Disorder Treatment Market by Drug Type
• 10.3 APAC Psychotic Disorder Treatment Market by Distribution Channel
• 10.4 Japanese Psychotic Disorder Treatment Market
• 10.5 Indian Psychotic Disorder Treatment Market
• 10.6 Chinese Psychotic Disorder Treatment Market
• 10.7 South Korean Psychotic Disorder Treatment Market
• 10.8 Indonesian Psychotic Disorder Treatment Market

11. ROW Psychotic Disorder Treatment Market

• 11.1 Overview
• 11.2 ROW Psychotic Disorder Treatment Market by Drug Type
• 11.3 ROW Psychotic Disorder Treatment Market by Distribution Channel
• 11.4 Middle Eastern Psychotic Disorder Treatment Market
• 11.5 South American Psychotic Disorder Treatment Market
• 11.6 African Psychotic Disorder Treatment Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunities by Drug Type
  • 13.2.2 Growth Opportunities by Indication
  • 13.2.3 Growth Opportunities by Distribution Channel
• 13.3 Emerging Trends in the Global Psychotic Disorder Treatment Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis
• 14.2 H. Lundbeck
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 Otsuka Pharmaceutical
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 Janssen Pharmaceuticals
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 Eli Lilly and Company
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Allergan
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 Teva Pharmaceutical Industries
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Dr. Reddy's Laboratories
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 Sumitomo Dainippon Pharma
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 Alkermes
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 Bristol-Myers Squibb Company
  • Company Overview
  • Psychotic Disorder Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us